Results 1 to 10 of about 366,020 (324)

Prostate-Specific Antigen [PDF]

, 2011
The use of PSA as a screening test for prostate cancer remains controversial because no double blind, randomised controlled trial has shown that early detection reduces mortality.1,2 Despite this controversy, PSA provides valuable information for the ...
Brett, Tom
openaire   +3 more sources

Prostate-Specific Antigen [PDF]

American Journal of Clinical Pathology, 2006
Prostate cancer is a highly prevalent disease that is characterized by a wide range of aggressiveness, ranging from the clinically irrelevant to the rapidly progressive, lethally metastatic. Since its introduction as a serum test in the late 1980s, prostate-specific antigen (PSA) has been increasingly promulgated as an important biomarker for prostate ...
Kristin R. Swanson, Hana L.P. Harpold, Lawrence D. True   +2 more
  +5 more sources

Usefulness of prostate specific antigen density in detecting prostate carcinoma: A hospital-based study in patients with prostate biopsies

Journal of Pathology of Nepal, 2022
Background: Prostate-specific antigen density has been suggested to enhance the diagnostic efficacy of serum prostate-specific antigen alone in detecting prostate cancer, thereby reducing unnecessary biopsies and associated morbidities.
Reshmi Shrestha, Shova Kunwar, Suman Gurung, Anjana Nuri Pokharel   +3 more
doaj   +1 more source

Prostate-specific antigen

Seminars in Surgical Oncology, 2000
Prostate-specific antigen (PSA) has revolutionized the diagnosis and management of men with prostate cancer. Significant advances have been made since the early development of immunoassays. While PSA is useful for staging and monitoring of established disease, it has shown the greatest utility in the realm of early detection realm.
D K, Ornstein, R S, Pruthi
  +8 more sources

Clinical application of free/total PSA ratio in the diagnosis of prostate cancer in men over 50 years of age with total PSA levels of 2.0–25.0 ng ml-1 in Western China

Asian Journal of Andrology, 2022
The goal of this study was to investigate the clinical application of free/total prostate-specific antigen (F/T PSA) ratio, considering the new broad serum total PSA (T-PSA) “gray zone” of 2.0–25.0 ng ml−1 in differential diagnosis of prostate cancer ...
Xue-Dan Gao, Qiang Miao, Jun-Long Zhang, Jian-Zhao Zhai, Xue-Mei Gui, Yi-Han Cai, Qian Niu, Bei Cai   +7 more
doaj   +1 more source

Body mass index in relation to prostate-specific antigen-related parameters

BMC Urology, 2021
Background Only a few previous studies conducted to assess the association between body mass index (BMI) and prostate-specific antigen (PSA) related parameters have taken prostate volume (PV) and blood volume (BV) into consideration.
Dandan Lin, Ting Liu, Luling Chen, Zongtao Chen   +3 more
doaj   +1 more source

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review

Oncology Reviews, 2020
Prostate-specific antigen velocity (PSAV) is widely used to detect PC and predict its progression. In this study, we qualitatively synthesized the currently available evidence from published studies regarding the PSAV role in PC.
Arslaan Javaeed, Sanniya Khan Ghauri, Abdellatif Ibrahim, Mohamed Fahmy Doheim   +3 more
doaj   +1 more source

The Efficiency of the Serum Prostate Specific Antigen Levels in Diagnosing Prostatic Enlargements [PDF]

Journal of Clinical and Diagnostic Research, 2013
Background: The objective of this study was to evaluate the serum PSA levels in patients presenting with enlarged prostate and to evaluate the efficiency of serum PSA to diagnose and differentiate benign and malignant enlargements.
Ingle SP, Ingle Ramona, Sukesh
doaj   +1 more source

Evaluation of Phage Display Discovered Peptides as Ligands for Prostate-Specific Membrane Antigen (PSMA) [PDF]

, 2013
The aim of this study was to identify potential ligands of PSMA suitable for further development as novel PSMA-targeted peptides using phage display technology. The human PSMA protein was immobilized as a target followed by incubation with a 15-mer phage
A Ghosh, AC Pawlyk, AM Quinn, CW Diehnelt, D Hessels, D Shen, DB Sodee, Duanwen Shen, E Basch, F Yi, Fei Xie, GA Lazar, H Liu, H Liu, H-S Lim, HD Agnew, IM Thompson, Irina U. Agoulnik, J Yu, JA Arter, JR Mesters, JR Newton, KA Noren, MI Davis, MI Milowsky, MJ Morris, MJ Morris, MJ Roobol, NH Bander, RK Nam, S Aggarwal, S Kim, S Minner, SE Lupold, SM Hillier, SR Banerjee, SR Banerjee, SR Banerjee, SR Banerjee, SS Chang, SZ Li, TJ Wigle, V Humblet, W. Barry Edwards, Y Chen, Y Chen, Y Chen, Z Xiao, ZY Zhu   +48 more
core   +16 more sources

Oral ethinylestradiol in castration resistent prostate cancer: 10 year experience [PDF]

, 2015
To describe our 10-year experience with the use of oral ethinylestradiol in the treatment of metastatic castration-resistant prostate cancer. METHODS: From February 2000 to April 2010, 116 patients with a metastatic castration-resistant prostate cancer
Aggarwal, Beer, Bonkhoff, Bono, Chadha, Corey, Di Silverio, Gasent Blesa, Izumi, Kitahara, Limonta, Montgomery, Shamash, Stein, Takezawa, Tannock, Wilkins   +16 more
core   +1 more source